Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
22
10
2021
accepted:
03
02
2022
pubmed:
25
3
2022
medline:
16
4
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma
Identifiants
pubmed: 35322232
doi: 10.1038/s41586-022-04508-4
pii: 10.1038/s41586-022-04508-4
pmc: PMC8967713
doi:
Substances chimiques
B7-H1 Antigen
0
Ipilimumab
0
Nivolumab
31YO63LBSN
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
942-948Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Catenacci, D. V. T. et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1467–1482 (2017).
doi: 10.1016/S1470-2045(17)30566-1
Fuchs, C. S. et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 420–435 (2019).
doi: 10.1016/S1470-2045(18)30791-5
Lordick, F. et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 490–499 (2013).
doi: 10.1016/S1470-2045(13)70102-5
Shah, M. A. et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 3, 620–627 (2017).
doi: 10.1001/jamaoncol.2016.5580
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
doi: 10.1016/S0140-6736(21)00797-2
OPDIVO (Nivolumab) Injection for Intravenous Use. Prescribing Information (Bristol Myers Squibb, 2021).
Das, R. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950–959 (2015).
doi: 10.4049/jimmunol.1401686
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).
doi: 10.1200/JCO.2009.26.7609
Wang, C. et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2, 846–856 (2014).
doi: 10.1158/2326-6066.CIR-14-0040
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
doi: 10.1038/nrc3239
Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).
doi: 10.1158/2159-8290.CD-18-0367
Janjigian, Y. Y. et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36, 2836–2844 (2018).
doi: 10.1200/JCO.2017.76.6212
Shitara, K. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6, 1571–1580 (2020).
doi: 10.1001/jamaoncol.2020.3370
Lei, M. et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab ± ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin. Cancer Res. 27, 3926–3935 (2021).
doi: 10.1158/1078-0432.CCR-20-2790
Hagi, T. et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br. J. Cancer 123, 965–972 (2020).
doi: 10.1038/s41416-020-0975-7
Fassan, M. et al. PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Arch. 477, 151–156 (2020).
doi: 10.1007/s00428-019-02693-8
Xu, J. et al. LBA53–Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann. Oncol. 32, S1283–S1346 (2021).
doi: 10.1016/j.annonc.2020.10.600
Xu, J., Jin, Y., Liu, Y., Zhou, H. & Wang, Y. ORIENT-16: sintilimab plus XELOX vs placebo plus XELOX as 1st line treatment for unresectable advanced gastric and GEJ adenocarcinoma. Cancer Res. 79, CT213 (2019).
Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449–462 (2022).
doi: 10.1056/NEJMoa2111380
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
doi: 10.1056/NEJMoa1712126
Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021).
doi: 10.1016/S0140-6736(20)32714-8
Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
doi: 10.1056/NEJMoa1910231
Bang, Y. J. et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29, 2052–2060 (2018).
doi: 10.1093/annonc/mdy264
Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018).
doi: 10.1016/S0140-6736(18)31257-1
Bass, A. J. et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
doi: 10.1038/nature13480
Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
doi: 10.1038/nature20805
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
doi: 10.1056/NEJMoa1709684
Angell, H. K. et al. PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. OncoImmunology 8, e1544442 (2019).
doi: 10.1080/2162402X.2018.1544442
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
doi: 10.1126/science.aan6733
Zhou, K. I. et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res. 26, 6453–6463 (2020).
doi: 10.1158/1078-0432.CCR-20-2085
Garland, S. N. et al. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer 117, 1302–1312 (2011).
doi: 10.1002/cncr.25556
Kulangara, K. et al. Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS). J Clin Oncol 36, 4065 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.4065